| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 4th January 2021 | Mark Alan Goldberg | 3,452 | Grant/award etc. | $4.02 | $13,877.04 |
| 24th December 2020 | Mark Alan Goldberg | 5,455 | Open or private sale | $125.00 | $681,875.00 |
| 24th December 2020 | Mark Alan Goldberg | 5,455 | Exercise of derivative | $28.15 | $153,558.25 |
| 18th December 2020 | Mark Alan Goldberg | 5,454 | Exercise of derivative | $28.15 | $153,530.10 |
| 18th December 2020 | Mark Alan Goldberg | 5,454 | Open or private sale | $120.00 | $654,480.00 |
| 17th December 2020 | Charles A Jr Rowland | 10,909 | Exercise of derivative | $19.53 | $213,052.77 |
| 17th December 2020 | Charles A Jr Rowland | 10,909 | Open or private sale | $117.82 | $1,285,298.38 |
| 14th December 2020 | Marion Dorsch | 4,600 | Exercise of derivative | $37.11 | $170,706.00 |
| 14th December 2020 | Jeffrey W. Albers | 5,000 | Open or private sale | $119.18 | $595,900.00 |
| 14th December 2020 | Jeffrey W. Albers | 5,000 | Exercise of derivative | $8.80 | $44,000.00 |
Blueprint Medicines
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Blueprint Medicines Corp. focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy in 2008.
Ticker: BPMC
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1597264
Employees: 383
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $289 M (0%)
Inventory, Net: $4 M (0%)
Assets, Current: $568 M (9%)
Property, Plant and Equipment, Net: $37 M (0%)
Other Assets, Noncurrent: $8 M (-18%)
Assets: $817 M (15%)
Accounts Payable, Current: $6 M (16%)
Accrued Liabilities, Current: $84 M (0%)
Liabilities, Current: $105 M (-1%)
Other Liabilities, Noncurrent: $9 M (9%)
Liabilities: $236 M (-2%)
Common Stock, Value, Issued: $54 Th (10%)
Common Stock, Shares, Issued: $54 M (10%)
Retained Earnings (Accumulated Deficit): $1 B (24%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $1 M (-55%)
Stockholders' Equity (Parent): $581 M (0%)
Liabilities and Equity: $817 M (15%)
Cost of Revenue: $127 Th (-15%)
Research and Development: $91 M (-48%)
Other Income, net: $2 M (-63%)
